Status:
TERMINATED
The Use of REZUM System in Chinese Male Patients With LUTS Secondary to Benign Prostate Enlargement
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Benign Prostatic Hyperplasia
Eligibility:
MALE
50-80 years
Phase:
NA
Brief Summary
Men with enlarged prostates commonly experience lower urinary tract symptoms and may go on to develop complications such as acute urinary retention (AUR). Surgery is the standard treatment option requ...
Detailed Description
Benign prostatic enlargement (BPE) is a non-malignant growth of the prostate gland that can lead to a range of lower urinary tract symptoms (LUTS), and in some cases eventually leading to retention of...
Eligibility Criteria
Inclusion
- Men aged between 50 - 80 years
- clinically indicated for surgical treatment
Exclusion
- Patients with active urinary tract infection or in retention of urine
- Patients with bleeding disorder or on anti-coagulation
- Patients with bladder pathology including bladder stone and bladder cancer
- Patients with urethral stricture
- Patients with neurogenic bladder and/or sphincter abnormalities
- Patients with previous nonpharmacological prostate treatment, Prostate cancer
- Fail to give informed consent
Key Trial Info
Start Date :
May 13 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 29 2021
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04340934
Start Date
May 13 2020
End Date
January 29 2021
Last Update
June 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Shatin, Hong Kong